ATE542535T1 - Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten - Google Patents

Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten

Info

Publication number
ATE542535T1
ATE542535T1 AT06724715T AT06724715T ATE542535T1 AT E542535 T1 ATE542535 T1 AT E542535T1 AT 06724715 T AT06724715 T AT 06724715T AT 06724715 T AT06724715 T AT 06724715T AT E542535 T1 ATE542535 T1 AT E542535T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
azapaullone
autoimmune diseases
pancreatic autoimmune
Prior art date
Application number
AT06724715T
Other languages
English (en)
Inventor
Rainer Mussmann
Conrad Kunick
Hendrik Stukenbrock
Marcus Geese
Simone Kegel
Ulrike Burk
Original Assignee
Develogen Ag
Tech Uni Carolo Wilhelmina Zu Braunschweig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Tech Uni Carolo Wilhelmina Zu Braunschweig filed Critical Develogen Ag
Application granted granted Critical
Publication of ATE542535T1 publication Critical patent/ATE542535T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06724715T 2005-05-04 2006-05-04 Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten ATE542535T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05009846 2005-05-04
EP05015986 2005-07-22
EP05023168 2005-10-24
EP06001327 2006-01-23
PCT/EP2006/004186 WO2006117221A1 (en) 2005-05-04 2006-05-04 Use of azapaullones for preventing and treating pancreatic autoimmune disorders

Publications (1)

Publication Number Publication Date
ATE542535T1 true ATE542535T1 (de) 2012-02-15

Family

ID=36625260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724715T ATE542535T1 (de) 2005-05-04 2006-05-04 Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten

Country Status (4)

Country Link
US (1) US7968535B2 (de)
EP (1) EP1879591B8 (de)
AT (1) ATE542535T1 (de)
WO (1) WO2006117221A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240481A1 (de) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinon)-substituierte pyridoindole als mch-antagonisten
WO2010123919A2 (en) 2009-04-20 2010-10-28 Auspex Pharmaceuticals, Llc Piperidine inhibitors of janus kinase 3
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
EP2448585B1 (de) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinon-substituiertes azepin[b]indol und pyrido-pyrrolo-azepin mch-1 antagonisten, verfahren zur herstellung und verwendung davon
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088157A2 (en) * 2010-12-22 2012-06-28 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists for islet cell transplantation
EP3920885A1 (de) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproinsäureverbindungen und wnt-agonisten zur behandlung von ohrerkrankungen
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
DE10290025T1 (de) * 2001-04-19 2003-10-09 Develogen Ag Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen
CA2455753A1 (en) 2001-08-03 2003-02-13 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
CN1646535A (zh) * 2002-02-22 2005-07-27 帝人株式会社 吡咯并嘧啶衍生物
JP4414232B2 (ja) * 2002-03-05 2010-02-10 イーライ リリー アンド カンパニー キナーゼ阻害物質
US8048454B2 (en) * 2004-03-09 2011-11-01 Michael Martin Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (GSK-3)
WO2005104836A2 (en) * 2004-04-16 2005-11-10 Albert Einstein College Of Medicine Of Yeshiva University Drosophila models for diseases affecting learning and memory

Also Published As

Publication number Publication date
EP1879591A1 (de) 2008-01-23
US7968535B2 (en) 2011-06-28
US20080287423A1 (en) 2008-11-20
EP1879591B8 (de) 2012-04-04
EP1879591B1 (de) 2012-01-25
WO2006117221A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
NL301145I2 (nl) Tirbanibulin
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
MX2007009807A (es) Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento.
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE521608T1 (de) Glucokinaseaktivatoren
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
TW200716140A (en) Treatment of inflammatory conditions
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
TWI319708B (en) Methods and compositions for altering cell fuction
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
TW200716132A (en) Novel chemical compounds
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.
DE602006018725D1 (de) Amidin-derivate zur verwendung in der vorbeugung oder behandlung von glaukom